Hypophosphatemia Data From AMAG Phase 3 Trial Presented at the American Society of Nephrology
Data Shows Patients Treated with Feraheme® (ferumoxytol) were Less Likely to Develop Severe Hypophosphatemia Compared to Those Treated with a Comparator IV Iron WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) …